产品
编 号：F502734
分子式：C30H45NNaO7P
分子量：585.64
分子式：C30H45NNaO7P
分子量：585.64
产品类型
规格
价格
是否有货
50mg
1143
In-stock
100mg
1592
In-stock
结构图
CAS No: 88889-14-9
产品详情
生物活性：
Fosinopril Sodium is the ester prodrug of an angiotensin-converting enzyme (ACE) inhibitor, used for the treatment of hypertension and some types of chronic heart failure.
体内研究：
Fosinopril (orally; 4.67 mg/kg; 4 weeks) downregulates the creatine kinase (CK) and lactate dehydrogenase (LDH) levels and against cardiac dysfunction and structural alteration.Fosinopril (orally; 4.67 mg/kg; 4 weeks) suppresses cleaved-caspase 3 expression and myocardial apoptosis in AMI rat model.Animal Model:HF post-acute myocardial infarction (AMI) rat model (SPF-grade Sprague-Dawley (SD) rats, 265 ± 15 g)
Dosage:4.67 mg/kg
Administration:p.o.; 4 weeks
Result:Against cardiac dysfunction and structural alteration and suppressed apoptosis.
体外研究：
Fosinopril (0, 1, 10, 33, 100μM; 30 min) partially inhibits the cosedimentation of liposomes and recombinant LPLA2.Fosinopril (250 nM) shows no inhibition of the soluble esterase activity of LPLA2.Fosinopril (0.372, 0.744, 1.116 μM) displays a non-competitive inhibition effect on ACE activity with a Ki value of 1.675 μM.
Fosinopril Sodium is the ester prodrug of an angiotensin-converting enzyme (ACE) inhibitor, used for the treatment of hypertension and some types of chronic heart failure.
体内研究：
Fosinopril (orally; 4.67 mg/kg; 4 weeks) downregulates the creatine kinase (CK) and lactate dehydrogenase (LDH) levels and against cardiac dysfunction and structural alteration.Fosinopril (orally; 4.67 mg/kg; 4 weeks) suppresses cleaved-caspase 3 expression and myocardial apoptosis in AMI rat model.Animal Model:HF post-acute myocardial infarction (AMI) rat model (SPF-grade Sprague-Dawley (SD) rats, 265 ± 15 g)
Dosage:4.67 mg/kg
Administration:p.o.; 4 weeks
Result:Against cardiac dysfunction and structural alteration and suppressed apoptosis.
体外研究：
Fosinopril (0, 1, 10, 33, 100μM; 30 min) partially inhibits the cosedimentation of liposomes and recombinant LPLA2.Fosinopril (250 nM) shows no inhibition of the soluble esterase activity of LPLA2.Fosinopril (0.372, 0.744, 1.116 μM) displays a non-competitive inhibition effect on ACE activity with a Ki value of 1.675 μM.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备